Cassava Sciences will discontinue developing simufilam for mild to moderate Alzheimer’s disease by the end of the second quarter of this year after the experimental treatment failed to meet key Phase 3 trial goals for improving cognition and daily function. In REFOCUS-ALZ (NCT05026177), patients treated with simufilam showed no significant improvements in cognitive functioning, as […] The post Simufilam fails to meet Phase 3 trial goals; development discontinued appeared first on Alzheime...
